Symbols / ELTX Stock $10.80 -4.93% Elicio Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
ELTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert T. Connelly
Exch · Country NCM · United States
Market Cap 198.68M
Enterprise Value 194.63M
Income -39.57M
Sales —
FCF (ttm) -21.67M
Book/sh 0.09
Cash/sh 1.01
Employees 33
Insider 10d —
IPO Feb 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.71
PEG —
P/S —
P/B 117.39
P/C —
EV/EBITDA -5.19
EV/Sales —
Quick Ratio 2.29
Current Ratio 2.38
Debt/Eq 887.04
LT Debt/Eq —
EPS (ttm) -2.58
EPS next Y -1.40
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-12
Earnings (prior) 2026-03-12
ROA -87.24%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 18.40M
Shs Float 12.71M
Insider Own 30.88%
Instit Own 14.15%
Short Float 11.33%
Short Ratio 13.28
Short Interest 1.44M
52W High 14.93
vs 52W High -27.66%
52W Low 4.85
vs 52W Low 122.68%
Beta 1.88
Impl. Vol. 6.25%
Rel Volume 0.67
Avg Volume 143.06K
Volume 95.41K
Target (mean) $17.50
Tgt Median $17.50
Tgt Low $17.00
Tgt High $18.00
# Analysts 2
Recom Strong_buy
Prev Close $11.36
Price $10.80
Change -4.93%
About

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.50
Mean price target
2. Current target
$10.80
Latest analyst target
3. DCF / Fair value
$-21.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.80
Low
$17.00
High
$18.00
Mean
$17.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 init Ladenburg Thalmann — → Buy $20
2026-03-13 main HC Wainwright & Co. Buy → Buy $17
2026-03-10 init Rodman & Renshaw — → Buy $17
2025-07-17 main HC Wainwright & Co. Buy → Buy $13
2025-04-02 reit HC Wainwright & Co. Buy → Buy $10
2024-10-31 init Jones Trading — → Buy $9
2024-08-23 reit HC Wainwright & Co. Buy → Buy $10
2024-06-06 reit HC Wainwright & Co. Buy → Buy $10
2024-05-22 reit HC Wainwright & Co. Buy → Buy $10
2024-05-01 main HC Wainwright & Co. Buy → Buy $10
2024-04-01 reit Oppenheimer Perform → Perform —
2024-01-17 main HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest ELTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 CONNELLY ROBERT Chief Executive Officer — 73,600 $0.00 $0
2026-02-02 HAQQ CHRISTOPHER Officer — 25,400 $0.00 $0
2026-02-02 SHAH PREETAM Chief Financial Officer — 24,000 $0.00 $0
2025-12-09 DEMUTH PETER Officer — 362 $4.41 $1,596
2025-03-05 CHUDNOVSKY YEKATERINA Director and Beneficial Owner of more than 10% of a Class of Security — 3,500,573 $5.81 $20,338,329
2024-12-16 DEMUTH PETER Officer — 381 $4.41 $1,680
2024-11-26 VENKATESAN JAY R Director — 50,000 $0.01 $500
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
37.30
-17.09%
44.99
+25.85%
35.74
+50.61%
23.73
Research And Development
24.90
-26.01%
33.66
+41.12%
23.85
+31.74%
18.10
Selling General And Administration
12.81
+13.07%
11.33
-4.76%
11.90
+111.30%
5.63
General And Administrative Expense
12.81
+13.07%
11.33
-4.76%
11.90
+111.30%
5.63
Other Gand A
12.81
+13.07%
11.33
-4.76%
11.90
+111.30%
5.63
Other Operating Expenses
-0.41
—
—
—
Total Expenses
37.30
-17.09%
44.99
+25.85%
35.74
+50.61%
23.73
Operating Income
-37.30
+17.09%
-44.99
-25.85%
-35.74
-50.61%
-23.73
Total Operating Income As Reported
-37.71
+16.17%
-44.99
-25.85%
-35.74
-50.61%
-23.73
EBITDA
-37.31
+25.77%
-50.27
-52.48%
-32.97
-39.96%
-23.55
Normalized EBITDA
-35.40
+23.94%
-46.53
-36.05%
-34.20
-51.26%
-22.61
Reconciled Depreciation
1.13
-4.24%
1.18
+0.68%
1.17
+10.69%
1.06
EBIT
-38.44
+25.28%
-51.44
-50.70%
-34.14
-38.70%
-24.61
Total Unusual Items
-1.92
+48.69%
-3.73
-401.94%
1.24
+231.07%
-0.94
Total Unusual Items Excluding Goodwill
-1.92
+48.69%
-3.73
-401.94%
1.24
+231.07%
-0.94
Special Income Charges
0.00
-100.00%
0.00
-99.50%
0.60
+30150.00%
0.00
Other Special Charges
—
—
-0.60
-30150.00%
-0.00
Net Income
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Pretax Income
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Net Non Operating Interest Income Expense
-0.36
-210.87%
0.32
+146.94%
-0.69
+80.58%
-3.53
Interest Expense Non Operating
1.13
+149.01%
0.46
-57.03%
1.06
-70.56%
3.60
Net Interest Income
-0.36
-210.87%
0.32
+146.94%
-0.69
+80.58%
-3.53
Interest Expense
1.13
+149.01%
0.46
-57.03%
1.06
-70.56%
3.60
Interest Income Non Operating
0.78
-0.13%
0.78
+108.31%
0.37
+473.85%
0.07
Interest Income
0.78
-0.13%
0.78
+108.31%
0.37
+473.85%
0.07
Other Income Expense
-1.92
+73.53%
-7.23
-685.28%
1.24
+231.07%
-0.94
Other Non Operating Income Expenses
—
-3.50
—
—
Gain On Sale Of Security
-1.92
+48.73%
-3.73
-691.92%
0.63
+166.77%
-0.94
Tax Provision
0.00
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Net Income From Continuing Operation Net Minority Interest
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Net Income From Continuing And Discontinued Operation
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Net Income Continuous Operations
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Normalized Income
-37.66
+21.82%
-48.17
-32.21%
-36.43
-33.62%
-27.27
Net Income Common Stockholders
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Diluted EPS
-2.58
+39.29%
-4.25
+38.94%
-6.96
-158.18%
-2.70
Basic EPS
-2.58
+39.29%
-4.25
+38.94%
-6.96
-158.18%
-2.70
Basic Average Shares
15.31
+25.48%
12.20
+141.35%
5.06
-51.68%
10.46
Diluted Average Shares
15.31
+25.48%
12.20
+141.35%
5.06
-51.68%
10.46
Diluted NI Availto Com Stockholders
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Gain On Sale Of PPE
0.00
-100.00%
0.00
0.00
—
Total Other Finance Cost
—
3.50
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
25.86
-8.22%
28.18
+3.80%
27.15
Current Assets
19.31
-6.68%
20.69
+26.58%
16.35
Cash Cash Equivalents And Short Term Investments
18.56
+5.36%
17.62
+36.64%
12.89
Cash And Cash Equivalents
18.56
+5.36%
17.62
+36.64%
12.89
Prepaid Assets
0.68
-62.42%
1.80
-29.82%
2.56
Restricted Cash
0.00
-100.00%
1.18
+63.16%
0.72
Other Current Assets
0.07
-27.72%
0.10
-41.62%
0.17
Total Non Current Assets
6.55
-12.48%
7.49
-30.68%
10.80
Net PPE
5.08
-17.97%
6.19
-14.99%
7.28
Gross PPE
6.83
-11.73%
7.74
-9.05%
8.51
Accumulated Depreciation
-1.76
-13.14%
-1.55
-26.08%
-1.23
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.26
+6.61%
0.24
+0.00%
0.24
Construction In Progress
—
—
—
Other Properties
6.44
-12.54%
7.37
-9.46%
8.14
Leases
0.13
+0.00%
0.13
+0.00%
0.13
Non Current Prepaid Assets
0.77
+28.33%
0.60
-78.82%
2.83
Other Non Current Assets
0.70
+1.15%
0.70
+1.61%
0.69
Total Liabilities Net Minority Interest
24.23
-38.65%
39.49
+150.36%
15.77
Current Liabilities
8.11
-29.62%
11.52
+18.12%
9.76
Payables And Accrued Expenses
4.57
-35.99%
7.14
+13.76%
6.28
Payables
0.67
-35.26%
1.04
-76.24%
4.37
Accounts Payable
0.67
-35.26%
1.04
-76.24%
4.37
Current Accrued Expenses
3.90
-36.11%
6.10
+219.86%
1.91
Pensionand Other Post Retirement Benefit Plans Current
2.53
+9.34%
2.31
+25.04%
1.85
Current Debt And Capital Lease Obligation
1.01
+12.21%
0.90
-0.99%
0.91
Current Debt
—
—
—
Other Current Borrowings
—
—
—
Current Capital Lease Obligation
1.01
+12.21%
0.90
-0.99%
0.91
Current Deferred Liabilities
0.00
-100.00%
1.17
+68.44%
0.69
Other Current Liabilities
—
—
0.03
Total Non Current Liabilities Net Minority Interest
16.12
-42.37%
27.97
+364.72%
6.02
Long Term Debt And Capital Lease Obligation
13.50
-46.29%
25.14
+318.50%
6.01
Long Term Debt
9.41
-53.04%
20.03
—
Long Term Capital Lease Obligation
4.09
-19.80%
5.11
-15.02%
6.01
Other Non Current Liabilities
—
—
—
Preferred Securities Outside Stock Equity
—
—
0.00
Stockholders Equity
1.64
+114.46%
-11.31
-199.46%
11.37
Common Stock Equity
1.64
+114.46%
-11.31
-199.46%
11.37
Capital Stock
0.18
+61.82%
0.11
+14.58%
0.10
Common Stock
0.18
+61.82%
0.11
+14.58%
0.10
Preferred Stock
0.00
0.00
0.00
Share Issued
17.81
+61.31%
11.04
+14.82%
9.62
Ordinary Shares Number
17.80
+61.39%
11.03
+14.84%
9.60
Treasury Shares Number
0.01
+0.00%
0.01
+0.00%
0.01
Additional Paid In Capital
235.41
+28.63%
183.00
+18.97%
153.83
Retained Earnings
-233.67
-20.39%
-194.10
-36.50%
-142.20
Gains Losses Not Affecting Retained Earnings
-0.13
+27.43%
-0.17
+11.17%
-0.20
Treasury Stock
0.15
+0.00%
0.15
+0.00%
0.15
Other Equity Adjustments
-0.13
+27.43%
-0.17
+11.17%
-0.20
Total Equity Gross Minority Interest
1.64
+114.46%
-11.31
-199.46%
11.37
Total Capitalization
11.04
+26.61%
8.72
-23.31%
11.37
Working Capital
11.20
+22.15%
9.17
+39.09%
6.59
Invested Capital
11.04
+26.61%
8.72
-23.31%
11.37
Total Debt
14.51
-44.27%
26.04
+276.46%
6.92
Net Debt
—
2.42
—
Capital Lease Obligations
5.11
-15.00%
6.01
-13.17%
6.92
Net Tangible Assets
1.64
+114.46%
-11.31
-199.46%
11.37
Tangible Book Value
1.64
+114.46%
-11.31
-199.46%
11.37
Derivative Product Liabilities
2.62
-7.53%
2.83
+25609.09%
0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-36.95
+0.31%
-37.07
-13.38%
-32.69
-47.41%
-22.18
Cash Flow From Continuing Operating Activities
-36.95
+0.31%
-37.07
-13.38%
-32.69
-47.41%
-22.18
Net Income From Continuing Operations
-39.57
+23.75%
-51.90
-47.46%
-35.20
-24.77%
-28.21
Depreciation Amortization Depletion
1.13
-4.24%
1.18
+0.68%
1.17
+10.69%
1.06
Depreciation
1.13
-4.24%
1.18
+0.68%
1.17
+10.69%
1.06
Depreciation And Amortization
1.13
-4.24%
1.18
+0.68%
1.17
+10.69%
1.06
Other Non Cash Items
0.32
-62.15%
0.86
-24.65%
1.14
-68.41%
3.60
Stock Based Compensation
2.70
+85.74%
1.45
+23.16%
1.18
+103.63%
0.58
Operating Gains Losses
1.92
-74.07%
7.38
+896.66%
-0.93
-197.89%
0.95
Gain Loss On Investment Securities
1.92
-74.08%
7.39
+1830.21%
-0.43
-145.19%
0.94
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.00
-102.86%
0.10
+2525.00%
0.00
Change In Working Capital
-3.44
-187.02%
3.96
+7045.61%
-0.06
+62.00%
-0.15
Change In Prepaid Assets
0.98
-68.09%
3.07
+520.85%
-0.73
+61.04%
-1.87
Change In Payables And Accrued Expense
-2.35
-277.39%
1.33
-40.73%
2.24
+173.05%
0.82
Change In Accrued Expense
-1.99
-142.68%
4.66
+110.20%
2.22
+826.56%
-0.30
Change In Payable
-0.37
+89.01%
-3.33
-14582.61%
0.02
-97.96%
1.12
Change In Account Payable
-0.37
+89.01%
-3.33
-14582.61%
0.02
-97.96%
1.12
Change In Other Working Capital
-1.17
-346.11%
0.47
+164.02%
-0.74
-151.67%
1.44
Change In Other Current Assets
—
—
—
0.67
Change In Other Current Liabilities
-0.90
+1.10%
-0.91
-10.42%
-0.82
-54.21%
-0.54
Investing Cash Flow
-0.02
+80.95%
-0.08
-162.50%
-0.03
+95.11%
-0.65
Cash Flow From Continuing Investing Activities
-0.02
+80.95%
-0.08
-162.50%
-0.03
+95.11%
-0.65
Net PPE Purchase And Sale
-0.02
+80.95%
-0.08
-162.50%
-0.03
+95.11%
-0.65
Purchase Of PPE
-0.02
+81.61%
-0.09
-31.82%
-0.07
+89.91%
-0.65
Sale Of PPE
0.00
-100.00%
0.00
-91.18%
0.03
0.00
Capital Expenditure
-0.02
+81.61%
-0.09
-31.82%
-0.07
+89.91%
-0.65
Financing Cash Flow
36.70
-13.29%
42.32
+9.60%
38.61
+82.12%
21.20
Cash Flow From Continuing Financing Activities
36.70
-13.29%
42.32
+9.60%
38.61
+82.12%
21.20
Net Issuance Payments Of Debt
0.00
-100.00%
19.73
+97.27%
10.00
0.00
Issuance Of Debt
0.00
-100.00%
19.73
+97.27%
10.00
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
0.00
-100.00%
19.73
+97.27%
10.00
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
0.00
-100.00%
19.73
+97.27%
10.00
0.00
Net Common Stock Issuance
25.39
+350.52%
5.63
-19.49%
7.00
0.00
Common Stock Payments
—
—
-0.15
0.00
Repurchase Of Capital Stock
—
—
-0.15
0.00
Proceeds From Stock Option Exercised
11.31
-35.41%
17.51
+13685.83%
0.13
+54.88%
0.08
Net Other Financing Charges
—
-0.55
-102.56%
21.49
—
Changes In Cash
-0.27
-105.28%
5.17
-12.20%
5.89
+460.94%
-1.63
Effect Of Exchange Rate Changes
0.05
+118.18%
0.02
0.00
0.00
Beginning Cash Position
19.49
+36.30%
14.30
+69.97%
8.41
-16.24%
10.04
End Cash Position
19.27
-1.15%
19.49
+36.30%
14.30
+69.97%
8.41
Free Cash Flow
-36.97
+0.50%
-37.16
-13.42%
-32.76
-43.48%
-22.83
Common Stock Issuance
25.39
+350.52%
5.63
-19.49%
7.00
0.00
Issuance Of Capital Stock
25.39
+350.52%
5.63
-19.49%
7.00
-66.86%
21.12
Net Preferred Stock Issuance
—
—
0.00
-100.00%
21.12
Preferred Stock Issuance
—
—
0.00
-100.00%
21.12
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category